MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1313-1321

  Chai, Jie ^a   Wang, Shan ^a   Han, Dali ^a   Dong, Wei ^a   Xie, Chao ^a   Guo, Hongliang ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Colorectal cancer; Invasion; Kinase; miR 455 RAF; Proliferation; Proto oncogene; RAF1; Serine threonine protein

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 101; MICRORNA 455; MICRORNA 484; RAF PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; MIRN455 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 84923826027     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2766-3     Document Type: Article

References (36)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
4. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, et al. Diagnostic and prognostic microRNAs in stage ii colon cancer. Cancer Res. 2008;68:6416–24.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer J Int du Cancer. 2010;127:2893–917.
7. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. Mirna profiling in colorectal cancer highlights mir-1 involvement in met-dependent proliferation. Mol Cancer Res MCR. 2012;10:504–15.
8. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends cancer epidemiology, biomarkers & prevention. Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19:1893–907.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
10. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58:1284–92.
11. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18:244–52.
12. Michael MZ SMOC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res: MCR. 2003;1:882–91.
13. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer. Cancer Epidemiol Biomarkers Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc of Prev Oncol. 2011;20:1272–86.
14. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz Jr LA, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103:3687–92.
15. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA: J Am Med Assoc. 2008;299:425–36.
16. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.
17. Mattick JS, Makunin IV: Small regulatory RNAs in mammals. Human molecular genetics 2005;14 Spec No 1:R121-132.
18. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:2690–5.
19. Nagadia R, Pandit P, Coman WB, Cooper-White J, Punyadeera C. MiRNAs in head and neck cancer revisited. Cell Oncol. 2013;36:1–7.
20. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.
21. Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27:5848–56.
22. Wang YW, Shi DB, Chen X, Gao C, Gao P. Clinicopathological significance of microRNA-214 in gastric cancer and its effect on cell biological behaviour. PLoS ONE. 2014;9:e91307.
23. Li Y, Li W, Zhang JG, Li HY, Li YM: Downregulation of tumor suppressor menin by mir-421 promotes proliferation and migration of neuroblastoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2014
24. Ma Y, She XG, Ming YZ, Wan QQ: Mir-24 promotes the proliferation and invasion of hcc cells by targeting sox7. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2014
25. Wu JH, Yao YL, Gu T, Wang ZY, Pu XY, Sun WW, et al. Mir-421 regulates apoptosis of bgc-823 gastric cancer cells by targeting caspase-3. Asian Pac J Cancer Prev: APJCP. 2014;15:5463–8.
26. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, et al. Mir-195, mir-455-3p and mir-10a (*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010;296:241–8.
27. Hu Z, Shen WJ, Kraemer FB, Azhar S. MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class b type i in steroidogenic cells. Mol Cell Biol. 2012;32:5035–45.
28. Li X, Zhang G, Luo F, Ruan J, Huang D, Feng D, et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep. 2012;28:77–84.
29. Swingler TE, Wheeler G, Carmont V, Elliott HR, Barter MJ, Abu-Elmagd M, et al. The expression and function of microRNAs in chondrogenesis and osteoarthritis. Arthritis Rheum. 2012;64:1909–19.
30. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, et al. Raf-1 activates map kinase-kinase. Nature. 1992;358:417–21.
31. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, et al. A raf-induced allosteric transition of ksr stimulates phosphorylation of mek. Nature. 2011;472:366–9.
32. Li P, Wood K, Mamon H, Haser W, Roberts T. Raf-1: a kinase currently without a cause but not lacking in effects. Cell. 1991;64:479–82.
33. Xu ZH, Hang JB, Hu JA, Gao BL. Raf1-mek1-erk/akt axis may confer nsclc cell lines resistance to erlotinib. Int J Clin Exp Pathol. 2013;6:1493–504.
34. Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM, et al. Mir-16 inhibits cell proliferation by targeting igf1r and the raf1-mek1/2-erk1/2 pathway in osteosarcoma. FEBS Lett. 2013;587:1366–72.
35. Albers C, Illert AL, Miething C, Leischner H, Thiede M, Peschel C, et al. An RNAi-based system for loss-of-function analysis identifies raf1 as a crucial mediator of bcr-abl-driven leukemogenesis. Blood. 2011;118:2200–10.
36. Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N, et al. Molecular and clinical analysis of raf1 in noonan syndrome and related disorders: Dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010;31:284–94.